PowderJect to start vaccine trial
PowderJect is to start clinical trials of a vaccine to combat hepatitis B as part of its continuing strategic alliance with GlaxoSmithKline.
Oxford-based PowderJect, through its subsidiary PowderJect Vaccines, will study the effectiveness of a DNA immunotherapeutic treatment to combat hepatitis B, the chronic viral infection.
The Business Hub
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.





